Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase Ib Study of Single-Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Borazanci E, Pishvaian MJ, Nemunaitis J, Weekes C, Huang J, Rajakumaraswamy N. Borazanci E, et al. Among authors: rajakumaraswamy n. Oncologist. 2020 Nov;25(11):e1604-e1613. doi: 10.1634/theoncologist.2020-0321. Epub 2020 Jun 18. Oncologist. 2020. PMID: 32356383 Free PMC article. Clinical Trial.
Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas.
Wagner-Johnston ND, Schuster SJ, deVos S, Salles G, Jurczak WJ, Flowers CR, Viardot A, Flinn IW, Martin P, Xing G, Rajakumaraswamy N, Gopal AK. Wagner-Johnston ND, et al. Among authors: rajakumaraswamy n. Leuk Lymphoma. 2021 May;62(5):1077-1087. doi: 10.1080/10428194.2020.1855344. Epub 2020 Dec 10. Leuk Lymphoma. 2021. PMID: 33300385 Clinical Trial.
Retrospective Analysis of the Impact of Adverse Event-Triggered Idelalisib Interruption and Dose Reduction on Clinical Outcomes in Patients With Relapsed/Refractory B-Cell Malignancies.
Ma S, Chan RJ, Gu L, Xing G, Rajakumaraswamy N, Ruzicka BB, Wagner-Johnston ND. Ma S, et al. Among authors: rajakumaraswamy n. Clin Lymphoma Myeloma Leuk. 2021 May;21(5):e432-e448. doi: 10.1016/j.clml.2020.12.016. Epub 2020 Dec 24. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33516721 Free article.
A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel).
Eyre TA, Preston G, Kagdi H, Islam A, Nicholson T, Smith HW, Cursley AP, Ramroth H, Xing G, Gu L, Rajakumaraswamy N, Fegan C. Eyre TA, et al. Among authors: rajakumaraswamy n. Br J Haematol. 2021 Jul;194(1):69-77. doi: 10.1111/bjh.17475. Epub 2021 Jun 14. Br J Haematol. 2021. PMID: 34121184 Free PMC article.
Idelalisib immune-related toxicity is associated with improved treatment response.
Wagner-Johnston ND, Sharman J, Furman RR, Salles G, Brown JR, Robak T, Gu L, Xing G, Chan RJ, Rajakumaraswamy N, Gopal AK. Wagner-Johnston ND, et al. Among authors: rajakumaraswamy n. Leuk Lymphoma. 2021 Dec;62(12):2915-2920. doi: 10.1080/10428194.2021.1948038. Epub 2021 Jul 28. Leuk Lymphoma. 2021. PMID: 34319205 Free PMC article.
Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma.
Morschhauser F, Dyer MJS, Walter HS, Danilov AV, Ysebaert L, Hodson DJ, Fegan C, Rule SA, Radford J, Cartron G, Bouabdallah K, Davies AJ, Spurgeon S, Rajakumaraswamy N, Li B, Humeniuk R, Huang X, Bhargava P, Jürgensmeier JM, Salles G. Morschhauser F, et al. Among authors: rajakumaraswamy n. Leukemia. 2021 Jul;35(7):2108-2113. doi: 10.1038/s41375-020-01108-x. Epub 2020 Dec 17. Leukemia. 2021. PMID: 33328591 Free PMC article. Clinical Trial. No abstract available.
Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.
Kutsch N, Pallasch C, Tausch E, Böhme V, Ritgen M, Liersch R, Wacker A, Jacobs G, Trappe RU, Dreger P, Fischer K, Fink AM, Stilgenbauer S, Zhai S, Li B, Jürgensmeier JM, Rajakumaraswamy N, Bhargava P, Hallek M, Eichhorst BF. Kutsch N, et al. Among authors: rajakumaraswamy n. Hemasphere. 2022 Mar 8;6(4):e692. doi: 10.1097/HS9.0000000000000692. eCollection 2022 Apr. Hemasphere. 2022. PMID: 35284802 Free PMC article. No abstract available.
Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.
Kutsch N, Pallasch C, Decker T, Hebart H, Chow KU, Graeven U, Kisro J, Kroeber A, Tausch E, Fischer K, Fink AM, Wendtner CM, Ritgen M, Stilgenbauer S, Zhang D, Li B, Jürgensmeier JM, Rajakumaraswamy N, Bhargava P, Hallek M, Eichhorst B. Kutsch N, et al. Among authors: rajakumaraswamy n. Hemasphere. 2022 May 25;6(6):e729. doi: 10.1097/HS9.0000000000000729. eCollection 2022 Jun. Hemasphere. 2022. PMID: 35747845 Free PMC article. No abstract available.
21 results